MedTrace Logo

Response to Supplement and Placebo in GERD

NCT01915173 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-03-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the effects of a widely available over the counter supplement marketed for heartburn symptoms on symptoms and health-related quality of life in patients with gastroesophageal reflux disease (GERD). This study is designed as a pilot trial to assess safety and feasibility and to provide preliminary estimates of effect sizes.

Conditions

  • Gastroesophageal Reflux Disease (GERD)
  • Heartburn
  • Dyspepsia

Interventions

DRUG

Supplement

Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C

DRUG

Placebo

Lactose tablets

BEHAVIORAL

Expanded Interview

BEHAVIORAL

Standard Interview

Sponsors & Collaborators

Principal Investigators

  • Michelle Dossett, MD, PhD, MPH · Beth Israel Deaconess Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01915173 on ClinicalTrials.gov